知臨集團 APM 深 滬
已收盤 07-17 16:00:00 美东时间
0.70
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.70
- 總市值 570.06万
- 52周最高 44.70
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.00
- 委 比 0.00%
- 總股本 814.38万
- 歷史最高 3328.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.60
- 每 手 1
- 風險率 4.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aptorum Merges With DiamiR, Forms Niki BioSolutions
The latest announcement is out from Aptorum Group ( ($APM) ). On July 20, 2026,...
07-20 20:47
Aptorum Group Announces 1-For-10 Reverse Stock Split, Effective July 20; Proposed Merger With DiamiR Biosciences Anticipated To Close Around July 20
Aptorum Group Limited, a Cayman Islands exempted company with limited liability (NASDAQ: APM) ("Aptorum Group" or "Aptorum" or "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that the closing of its merger with DiamiR Biosciences Co...
07-16 23:03
Aptorum Group Provides Update on DiamiR Biosciences Merger
Aptorum Group and DiamiR Biosciences have finalized their merger, with the new company, Niki BioSolutions, Inc., set to trade on Nasdaq under "NIKI." The merger is expected to close on July 20, 2026. Aptorum is implementing a 1-for-10 reverse share split to increase its stock price and maintain compliance with Nasdaq listing requirements. The new company will be headquartered in Delaware and will combine Aptorum's biopharmaceutical expertise with...
07-16 15:00
Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference
Aptorum Group and DiamiR Biosciences announced their upcoming presentations at the Alzheimer’s Association International Conference (AAIC) 2026, showcasing DiamiR’s biomarker technologies. Alidad Mireskandari, DiamiR’s CEO, will present three abstracts focusing on plasma-based APOE genotyping, circulating microRNAs as biomarkers for Alzheimer’s progression, and an automated APOE genotyping method. The presentations highlight advancements in blood...
07-08 12:00
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers
Aptorum Group and DiamiR Biosciences have entered into a definitive agreement for a merger, with shareholders approving the transaction on June 9, 2026. The merger is expected to close before fiscal 2027, subject to customary closing conditions. Upon completion, DiamiR will become a wholly-owned subsidiary of Aptorum Group, and the combined company will be renamed Niki BioSolutions, Inc. The collaboration between DiamiR and AlzLabs aims to develo...
06-22 12:00
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
Aptorum Group shareholders approve merger with DiamiR Biosciences to form a leading life sciences company focused on improving patient outcomes. The all-stock transaction, expected to close before 2027, will make DiamiR a wholly owned subsidiary of Aptorum. Both companies' shareholders have approved the deal, which aims to accelerate commercialization and drive growth in brain health diagnostics.
06-10 12:00
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Aptorum Group Limited received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement of $1 per share. The company has been granted a 180-day grace period until September 1, 2026, to regain compliance. Aptorum intends to evaluate all options, including a reverse stock split, to restore compliance and maintain its Nasdaq listing.
03-06 21:30
Aptorum Group, DiamiR Biosciences, Instant NanoBiosensors Collaborate To Validate Instant's Automated APOE Testing Platform
Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative
02-02 21:06
